STOCK TITAN
  1. Home
  2. News
  3. SPRC

SciSparc Ltd - SPRC STOCK NEWS

Welcome to our dedicated news page for SciSparc (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SciSparc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SciSparc's position in the market.

News
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
Rhea-AI Summary
SciSparc Ltd. announces collaboration with Clearmind Medicine Inc. for patent applications on novel psychedelic-derived therapeutics, focusing on mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
partnership
-
News
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announces collaboration with Clearmind Medicine Inc. to develop novel psychedelic-derived therapeutics. Clearmind files three patent applications for proprietary combinations of LSD, psilocybin, DMT, and PEA with CannAmide™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.52%
Tags
none
-
News
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
Rhea-AI Summary
SciSparc Ltd. announces the initiation of patient recruitment for its clinical trial in Israel for SCI-210, a combination of cannabidiol (CBD) and CannAmide™, designed to alleviate symptoms of autism spectrum disorder (ASD). The goal is to commercialize SCI-210 first in Israel and then in other countries, subject to regulatory approvals. The trial aims to compare SCI-210 therapy to standard CBD treatment in managing ASD symptoms and has three primary efficacy metrics. The trial was designed in consultation with the National Autism Research Center in Israel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.43%
Tags
clinical trial
News
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
Rhea-AI Summary
SciSparc Ltd. has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global, LP, to purchase up to $20 million of the Company’s ordinary shares over the next thirty-six-month period. The purchase price of the ordinary shares will be at a 3% discount of the weighted average price of the Company's ordinary shares during a specific trading day period. The Company intends to use the proceeds for working capital and other general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.03%
Tags
none
-
News
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
Rhea-AI Summary
SciSparc Ltd. announced a bridge loan agreement with a leading vehicle importer company in Israel for the acquisition of the Target Company. The bridge loan amount is $1.4 million, with an interest rate of 7% per annum. The company intends to acquire 100% of the Target Company and establish a new wholly-owned Israeli subsidiary, with shareholders holding approximately 50.01% of the share capital of the resulting combined company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.77%
Tags
acquisition
-
News
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) reflect on a successful collaboration in 2023. Clearmind filed six provisional patent applications with the USPTO for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc. The patent applications aim to offer safer and more effective treatments for patients with mental health disorders, strengthening their IP portfolios and developing treatments that offer synergy, efficacy, and safety, while reducing the total cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.02%
Tags
none
News
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) achieved a significant milestone in its joint venture with MitoCareX Bio Ltd., focusing on cancer treatment drug discovery. MitoCareX Bio successfully developed laboratory capabilities for small-molecule screening platforms, targeting human mitochondrial carriers. This achievement led to SciSparc investing an additional $600,000, resulting in a 50.1% ownership of MitoCareX Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.51%
Tags
none
-
News
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) will acquire 100% of a leading vehicle importer company in Israel, establishing a new wholly-owned Israeli subsidiary. This follows the company's announcement in June 2022 to review potential strategic transactions to maximize shareholder value. The proposed Acquisition will result in SciSparc shareholders holding approximately 50.01% of the post-closing combined company, compared to 20% as previously announced. The Target Company's revenues for the first half of 2023 amounted to over $52 million. The Acquisition is subject to due diligence, execution of binding agreements, and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
acquisition
-
News
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) announced successful results from a pre-clinical trial for its obesity and metabolic disorder program in collaboration with Clearmind Medicine Inc. (Nasdaq: CMND). The trial focused on identifying the optimal dosage for the Combination Treatment, which includes palmitoylethanolamide (PEA) and MEAI, resulting in increased metabolic activity, reduced appetite, and enhanced fat oxidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
clinical trial
News
SciSparc Adopts Limited Duration Shareholder Rights Plan
Rhea-AI Summary
SciSparc Ltd. (SPRC) adopts a limited duration shareholder rights plan to protect the long-term interests of shareholders and enable them to realize the full potential value of their investment. The plan is designed to reduce the likelihood of any entity gaining control of the company without appropriately compensating all shareholders. The company's CEO, Oz Adler, emphasized the positive results from the weight loss and metabolic disorder program with a proprietary psychedelic-based treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
none
Stock SPRC logo
SciSparc Ltd

Nasdaq:SPRC

SPRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

SPRC Stock Data

4.11M
324.71k
0.02%
2.42%
6.6%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv